Aetna Inc (AET) Expected to Post Quarterly Sales of $15.26 Billion

Aetna Inc (AET) Expected to Post Quarterly Sales of $15.26 Billion

Analysts expect Aetna Inc (NYSE:AET) to report $15.26 billion in sales for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have issued estimates for Aetna’s earnings, with estimates ranging from $14.63 billion to $15.67 billion. Aetna posted sales of $15.9 billion during the same quarter last year, which would indicate a negative year-over-year growth rate of 4%. The business is scheduled to report its next quarterly earnings results on Tuesday, August 1st.

On average, analysts expect that Aetna will report full year sales of $15.26 billion for the current year, with estimates ranging from $59.28 billion to $61.42 billion. For the next year, analysts anticipate that the company will post sales of $63.97 billion per share, with estimates ranging from $61.32 billion to $67.2 billion. Zacks’ sales averages are an average based on a survey of analysts that follow Aetna.

Aetna (NYSE:AET) last issued its quarterly earnings results on Tuesday, May 2nd. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.36 by $0.35. Aetna had a net margin of 3.58% and a return on equity of 16.39%. The company earned $15.17 billion during the quarter, compared to analysts’ expectations of $15.39 billion. During the same quarter in the previous year, the company earned $2.30 EPS. Aetna’s revenue was down 3.4% on a year-over-year basis.

A number of analysts have weighed in on AET shares. Deutsche Bank AG started coverage on shares of Aetna in a research report on Wednesday, April 5th. They set a “hold” rating and a $135.00 target price for the company. Jefferies Group LLC reissued a “hold” rating and set a $133.00 target price on shares of Aetna in a research report on Thursday, April 13th. Cantor Fitzgerald reissued an “overweight” rating and set a $140.00 target price on shares of Aetna in a research report on Tuesday, February 21st. Zacks Investment Research downgraded shares of Aetna from a “buy” rating to a “hold” rating in a research report on Wednesday, April 5th. Finally, Royal Bank of Canada reissued a “buy” rating and set a $145.00 target price on shares of Aetna in a research report on Monday, April 24th. Eight analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $138.55.

Shares of Aetna (NYSE:AET) traded up 0.49% during midday trading on Wednesday, hitting $140.77. 1,466,007 shares of the stock traded hands. The firm’s 50-day moving average is $130.87 and its 200 day moving average is $125.09. The company has a market capitalization of $49.51 billion, a price-to-earnings ratio of 21.96 and a beta of 0.61. Aetna has a 52 week low of $104.59 and a 52 week high of $140.85.

The business also recently disclosed a quarterly dividend, which was paid on Friday, April 28th. Stockholders of record on Thursday, April 13th were given a dividend of $0.50 per share. This is an increase from Aetna’s previous quarterly dividend of $0.25. The ex-dividend date was Tuesday, April 11th. This represents a $2.00 annualized dividend and a dividend yield of 1.42%. Aetna’s dividend payout ratio (DPR) is 15.67%.

In other news, insider Shawn M. Guertin sold 29,602 shares of the firm’s stock in a transaction that occurred on Thursday, March 23rd. The shares were sold at an average price of $129.35, for a total transaction of $3,829,018.70. Following the completion of the sale, the insider now owns 44,880 shares of the company’s stock, valued at approximately $5,805,228. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Francis S. Soistman, Jr. sold 6,607 shares of the firm’s stock in a transaction that occurred on Wednesday, March 8th. The stock was sold at an average price of $131.98, for a total transaction of $871,991.86. Following the sale, the vice president now directly owns 23,454 shares of the company’s stock, valued at approximately $3,095,458.92. The disclosure for this sale can be found here. Company insiders own 0.90% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Toronto Dominion Bank boosted its position in shares of Aetna by 57.0% in the first quarter. Toronto Dominion Bank now owns 95,608 shares of the company’s stock worth $12,194,000 after buying an additional 34,719 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in shares of Aetna during the first quarter worth about $3,328,000. Commerce Bank boosted its position in shares of Aetna by 5.6% in the first quarter. Commerce Bank now owns 18,259 shares of the company’s stock worth $2,329,000 after buying an additional 964 shares in the last quarter. Engineers Gate Manager LP purchased a new position in shares of Aetna during the first quarter worth about $4,871,000. Finally, Sei Investments Co. boosted its position in shares of Aetna by 25.5% in the first quarter. Sei Investments Co. now owns 193,152 shares of the company’s stock worth $24,637,000 after buying an additional 39,259 shares in the last quarter. Institutional investors own 88.40% of the company’s stock.

Aetna Company Profile

Aetna Inc is a diversified healthcare benefits company. The Company operates through three segments: Health Care, Group Insurance and Large Case Pensions. It offers a range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, medical management capabilities, Medicaid healthcare management services, Medicare Advantage and Medicare Supplement plans, workers’ compensation administrative services and health information technology (HIT) products and services.

Get a free copy of the Zacks research report on Aetna (AET)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment